C. diff Testing: Why a Positive PCR Does Not Always Mean Infection

A positive Clostridioides difficile PCR test tells you that bacteria carrying the toxin gene are present in a stool sample. It does not tell you that those bacteria are actively producing toxin, and it does not tell you that C. difficile is the reason a patient has diarrhea. Many people carry toxigenic C. difficile in their gut without any illness at all, so a positive nucleic acid amplification test (NAAT) in the wrong patient can label harmless colonization as infection. That is why laboratories increasingly pair the sensitive gene test with a second test for free toxin, and why guidelines are strict about who should be tested at all.

The gene, the toxin, and the difference between them

C. difficile infection (CDI) is caused by toxins, chiefly toxin A and toxin B, that damage the lining of the colon. Testing tries to answer two separate questions. The first is whether toxin-capable organisms are present. The second is whether those organisms are actually producing toxin during this illness. A NAAT answers only the first. As a 2024 review in the Journal of Medical Microbiology puts it, a positive NAAT result indicates the presence of the toxin gene only, so on its own it cannot separate active infection from asymptomatic carriage.

The assays differ sharply in what they measure. NAATs are highly sensitive and specific for the gene, with sensitivity above 92 percent and specificity above 99 percent, which is exactly why they detect colonized patients so readily. Toxin enzyme immunoassays measure the toxin protein itself and are far less sensitive, roughly 75 percent, though quite specific at around 95 percent. A toxin-positive result therefore points more directly at the disease process that treatment is meant to interrupt.

The clinical weight of that gap shows up in outcomes. The same review reports that mortality attributed to CDI was much lower in patients who were NAAT-positive but toxin-negative than in those who were toxin-positive, on the order of 0.6 percent versus 8.4 percent. A large share of NAAT-positive, toxin-negative patients are carriers whose diarrhea has another cause.

How multistep algorithms try to separate carriage from infection

Because no single assay cleanly distinguishes colonization from infection, expert bodies recommend combining tests. The 2017 IDSA/SHEA guideline recommends using a stool toxin test as part of a multistep algorithm, such as glutamate dehydrogenase (GDH) plus toxin, or NAAT plus toxin, rather than a NAAT alone when a laboratory has no pre-agreed criteria for which specimens it will accept. The CDC clinical guidance echoes this, describing two-step testing that begins with a high-sensitivity screen (NAAT or GDH) and follows with a high-specificity toxin test.

The logic is a deliberate sequence. The first step is built to rule out: if the sensitive screen is negative, C. difficile is very unlikely and testing stops. If the screen is positive, the second step tries to rule in true infection by detecting free toxin. A patient who screens positive but has no detectable toxin sits in an intermediate zone that clinicians must read against the bedside picture rather than treat reflexively. This is also why the guideline grades its testing recommendations as weak: the algorithms improve specificity, but a discordant result still demands judgment.

The problem starts before the sample reaches the lab

No algorithm can rescue a specimen that should never have been collected. The single most important control is the pre-test decision about who and what to test. The IDSA/SHEA guideline restricts preferred testing to patients with unexplained, new-onset diarrhea of at least three unformed stools in 24 hours, and it makes a strong recommendation against testing stool from asymptomatic patients and against repeat testing within seven days during the same episode.

The CDC guidance is equally concrete about specimen quality. Laboratories should test only unformed stool, since a formed specimen cannot represent active diarrheal illness. Clinicians are told to weigh other infectious and non-infectious causes of diarrhea first, and to stop laxatives and wait at least 48 hours before testing, because laxative-driven loose stool in a colonized patient is a classic source of false attribution.

Colonization is common, so the denominator matters

These rules exist because carriage is not rare. A 2025 systematic review and meta-analysis in Gut Pathogens pooled 51 studies covering nearly 40,000 patients and estimated the prevalence of toxigenic C. difficile asymptomatic colonization at about 7.6 percent overall (95% CI 5.7 to 9.7), and about 8.6 percent among patients tested at hospital admission. Individual cohorts ranged from under 1 percent to more than 50 percent depending on the population.

That baseline shapes interpretation directly. When a meaningful fraction of patients already carry the organism, testing people with a low probability of disease, those with formed stool, minimal symptoms, or an obvious alternative explanation, produces positives that mostly reflect the background carriage rate rather than the illness in front of you. The test did not fail. It answered a question that should not have been asked.

The downstream cost of a misread positive

Overdiagnosis is not a paperwork problem. A patient labeled with CDI is typically started on oral vancomycin or fidaxomicin, placed in contact isolation, and counted in facility infection metrics, while the true cause of the diarrhea goes unaddressed. Treating a colonized patient with antibiotics offers no benefit against a disease they do not have and further disrupts the gut community that resists C. difficile in the first place.

Diagnostic stewardship moves these numbers measurably. The Journal of Medical Microbiology review describes diagnostic stewardship, essentially enforcing the testing rules above, as cutting C. difficile test orders by roughly a third. Fewer inappropriate tests meant fewer misleading positives, which meant less unnecessary treatment.

One practical point follows from all of this. Once a test is positive, guidelines advise against repeat testing to confirm cure, because both NAAT and toxin assays can stay positive for six weeks or longer after symptoms resolve. A lingering positive reflects the biology of shedding, not persistent disease.

This article is educational and is not medical advice; testing and treatment decisions belong to a patient and their own clinicians.